Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AS1501 for injection in patients with acute-on-chronic liver failure
CTR20251006Phase 2Active
- Sponsor
- Shenzhen Zhongke Ai Shen Pharmaceutical
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AS1501 in acute-on-chronic liver failure (ACLF), hepatic failure, sponsored by Shenzhen Zhongke Ai Shen Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
AS1501
03
Conditions
acute-on-chronic liver failure (ACLF)hepatic failure
Beyond the preview
Go deeper on CTR20251006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251006.